Product Categories
| Country: | United States |
|---|---|
| Tel: | +1-781-999-5354 |
| Mobile: | +17819995354 |
| E-mail: | marketing@targetmol.com |
| QQ: | |
| Skype: | Chat Now! |
| Address: | 36?Washington?Street, Wellesley?Hills |
|
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
|
|
| Product Name | MF | CAS | Details |
|---|
| NSC305787 | C25H30Cl2N2O | 785718-37-8 | Details |
| NSC305787 hydrochloride | C25H31Cl3N2O | 53868-26-1 | Details |
| Ilginatinib | C21H20FN7 | 1239358-86-1 | Details |
| Fludazonium chloride | C26H20Cl4FN2O2*Cl | 53597-28-7 | Details |
| NSC624206 | C19H33Cl2NS2 | 13116-77-3 | Details |
| Cefuroxime axetil | C20H22N4O10S | 64544-07-6 | Details |
| NV-5138 | C7H13F2NO2 | 2095886-80-7 | Details |
| NTP42 | C25H23F2N3O5S | 2055599-51-2 | Details |
| NVP-CGM097 sulfate；CGM097 sulfate | C38H49ClN4O8S | 1313367-56-4 | Details |
| Ilginatinib maleate | C25H24FN7O4 | 1354799-87-3 | Details |
| Ilginatinib hydrochloride | C21H21ClFN7 | 1239358-85-0 | Details |
| NSP-805 | C17H19N3O2 | 125068-54-4 | Details |
| NXT629 | C35H39N5O3S | 1454925-59-7 | Details |
| NUCC-390 | C23H33N5O | 1060524-97-1 | Details |
| NVS-ZP7-4 | C28H28FN5OS | 2349367-89-9 | Details |
| Siremadlin (R Enantiomer)；HDM201 R Enantiomer;NVP-HDM201 R Enantiomer;Siremadlin R Enantiomer | C26H24Cl2N6O4 | 1448867-42-2 | Details |
| NVS-CRF38 | C19H21N5O2 | 1207258-55-6 | Details |
| NVP-QAV-572 | C17H19F2N7O3S2 | 957209-68-6 | Details |
| O-Desmethyl apixaban | C24H23N5O4 | 503612-76-8 | Details |
| Cefonicid sodium；Monocid sodium;Cefonicid disodium salt | C18H19N6NaO8S3 | 61270-78-8 | Details |
| O-Desmethyl Midostaurin；O-Desmethyl PKC412;CGP62221 | C34 H28 N4 O4 | 740816-86-8 | Details |
| Benzyl-α-GalNAc | C15H21NO6 | 3554-93-6 | Details |
| Ebopiprant | C30H34FN3O5S2 | 2005486-31-5 | Details |
| Erdosteine | C8H11NO4S2 | 84611-23-4 | Details |
| Odapipam；NNC 756 | C19H20ClNO2 | 131796-63-9 | Details |
| O-Propargyl-Puromycin | C24H29N7O5 | 1416561-90-4 | Details |
| Octadecanedioic acid | C18H34O4 | 871-70-5 | Details |
| O-Methyl Atorvastatin hemicalcium | C67H68Ca2F2N4O10 | 887196-29-4 | Details |
| Obtusifoliol | C30H50O | 16910-32-0 | Details |
| ODM-204 | C20H21F3N4 | 1642818-64-1 | Details |
| ON 146040 | C24H23N7O3S | 1404231-34-0 | Details |
| Oral antiplatelet agent 1 | C23H24N4O5S | 2299200-91-0 | Details |
| OMDM-3 | C29H43NO3 | 616884-64-1 | Details |
| OMDM-5 | C26H44N2O3 | 616884-66-3 | Details |
| OMDM-2 | C27H45NO3 | 616884-63-0 | Details |
| Pilocarpine nitrate | C11H17N3O5 | 148-72-1 | Details |
| Olanzapine D3；LY170053 D3 | C17H20N4S | 786686-79-1 | Details |
| OICR-0547 | C28H29F3N4O4 | 1801873-49-3 | Details |
| Org-10490 | C17H19NO | 83507-02-2 | Details |
| Olcegepant hydrochloride；BIBN-4096 hydrochloride;BIBN4096BS hydrochloride | C38H48Br2ClN9O5 | 586368-06-1 | Details |
| OR-1896 | C13H15N3O2 | 220246-81-1 | Details |
| Tirabrutinib hydrochloride | C25H23ClN6O3 | 1439901-97-9 | Details |
| OM-189 | C24H36N6O3S | 55381-18-5 | Details |
| OMDM-6 | C28H42N2O3 | 616884-67-4 | Details |
| OMDM-4 | C29H43NO3 | 616884-65-2 | Details |
| OMDM-1；(Z)-N-[(2S)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]octadec-9-enamide | C27H45NO3 | 616884-62-9 | Details |
| Olmesartan-d4；RNH-6270 D4;Olmesartan D4 | C24H22N6O3D4 | 1420880-41-6 | Details |
| OP-1074 | C29H31NO4 | 1443752-76-8 | Details |
| ORL1 antagonist 1 | C20H22ClN5 | 1174985-59-1 | Details |
| Olaparib-d5；Olaparib D5;KU0059436 D5;AZD2281 D5 | C24H23FN4O3 | 2143107-56-4 | Details |
| Opioid receptor modulator 1 | C18H23NO2 | 77514-44-4 | Details |
| Ophiobolin B | C25H38O4 | 5601-74-1 | Details |
| Oleuropeinic acid | C25H30O15 | 96382-90-0 | Details |
| Pamabrom | C11H18BrN5O3 | 606-04-2 | Details |
| Oligomycin B | C45H72O12 | 11050-94-5 | Details |
| Oligomycin C | C45H74O10 | 11052-72-5 | Details |
| Oleanolic acid hemiphthalate disodium salt | C38H53NaO6 | 168770-31-8 | Details |
| Olcegepant | C38H47Br2N9O5 | 204697-65-4 | Details |
| Oleoylethanolamide | C20H39NO2 | 111-58-0 | Details |
| Oleoylcarnitine | C25H47NO4 | 38677-66-6 | Details |
| ORM-10103 | C20H16N2O4 | 488847-28-5 | Details |
| Mepyramine maleate | C21H27N3O5 | 59-33-6 | Details |
| Orelabrutinib | C26H25N3O3 | 1655504-04-3 | Details |
| Org30958 | C21H30O2S2 | 99957-90-1 | Details |
| Omeprazole-d3；H 16868 D3;Omeprazole D3 | C17H16D3N3O3S | 922731-01-9 | Details |
| Omeprazole metabolite Omeprazole sulfone | C17H19N3O4S | 88546-55-8 | Details |
| ORM-10962 | C27H29N3O4 | 763926-98-3 | Details |
| Orotic acid-6-C14 | C5H4N2O4 | 13186-54-4 | Details |
| Oxolinic acid | C13H11NO5 | 14698-29-4 | Details |
| Ornidazole (Levo-) | C7H10ClN3O3 | 166734-83-4 | Details |
| OSMI-2 | C26H25N3O7S2 | 2260542-60-5 | Details |
| ORM-15341 | C19H17ClN6O2 | 1297537-33-7 | Details |
| OSMI-3 | C32H35N3O9S2 | 2260791-13-5 | Details |
| OSMI-4 | C27H26ClN3O7S2 | 2260791-14-6 | Details |
| Palbinone | C22H30O4 | 139954-00-0 | Details |
| p53 and MDM2 proteins-interaction-inhibitor (racemic)；p53-and-mdm2-proteins-interaction-inhibitor-racemic | C40H49Cl2N5O4 | 939983-14-9 | Details |
| ARRY-797 | C22H26F2N4O2 | 1034189-82-6 | Details |
| P-gp modulator 1 | C41H72N2O6 | 2249749-39-9 | Details |
| Benzquinamide；BZQ;Benzoquinamide;P2647 | C22H32N2O5 | 63-12-7 | Details |
| OTS186935 | C25H26ClN5O2 | 2093400-18-9 | Details |
| OTS186935 trihydrochloride | C25H27Cl2N5O2 | 2093401-85-3 | Details |
| P-gp inhibitor 1 | C32H31N5O2 | 2050747-49-2 | Details |
| CBP/p300-IN-3 | C24H29N7O | 2299226-01-8 | Details |
| OT-R antagonist 2；Oxytocin receptor antagonist 2 | C28H29N3O4 | 364071-16-9 | Details |
| OT-R antagonist 1；Oxytocin receptor antagonist 1 | C28H29N3O4 | 364071-17-0 | Details |
| OT antagonist 1 | C22H22N4O3 | 479080-38-1 | Details |
| OT antagonist 3 | C21H20N6O2 | 925703-75-9 | Details |
| p53 and MDM2 proteins-interaction-inhibitor (chiral)；p53-and-mdm2-proteins-interaction-inhibitor-chiral | C40H49Cl2N5O4 | 939981-37-0 | Details |
| Oxotremorine M iodide | C11H19IN2O | 3854-04-4 | Details |
| Oxythiamine diphosphate | C12H17N3O8P2S | 10497-04-8 | Details |
| Oxythiamine；Hydroxythiamin | C12H17Cl2N3O2S | 136-16-3 | Details |
| Oxidopamine hydrobromide | C8H12BrNO3 | 636-00-0 | Details |
| Oxidopamine hydrochloride | C8H12ClNO3 | 28094-15-7 | Details |
| Lincomycin hydrochloride monohydrate | C18H37ClN2O7S | 7179-49-9 | Details |
| CBP/p300-IN-5；P300/CBP-IN-5 | C29H27F5N6O4 | 1889284-33-6 | Details |
| OT-82 | C26H21FN4O | 1800487-55-1 | Details |
| p38-α MAPK-IN-1 | C27H35N5O3 | 443913-15-3 | Details |
| Oxaquin；MCB-3837;DNV3837 | C31H33F2N4O11P | 790704-50-6 | Details |
| OXFBD04 | C17H16N2O3 | 2231747-03-6 | Details |
| 5,5-Dimethyloxazolidine-2,4-dione | C5H7NO3 | 695-53-4 | Details |
| Product Total： Product Page： | ||||
| 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 | ||||